肥胖亚型的自然史:弗雷明汉心脏研究二十年的动态变化与预后
弗雷明汉后代队列研究纳入4291名参与者共26508次观察,评估代谢健康肥胖等四种肥胖亚型的动态变化及与结局的关联。中位随访14年,MHO患者4年内约43%-46%转为MUO,且相比MHNO仍有更高的糖尿病和高血压风险。MHO亚型是未来风险的预兆。
要点
- MHO患者4年内约43%-46%转为MUO,多数最终出现代谢异常和临床疾病。
- 相比MHNO,MHO的糖尿病风险HR为4.69,高血压风险HR为2.21。
- 相比MUO,MHO的糖尿病、CVD和CKD风险更低,但高血压和死亡风险相似。
核心结论
- 随时间推移,大多数MHO参与者出现代谢异常和临床疾病,MHO亚型是未来风险的预兆。
研究设计与样本
- 弗雷明汉后代队列研究,纳入4291名参与者,共26508次观察,随访中位14年。
主要发现
- 基线时4%为MHO,31%为MUNO;MHO者4年内转为MUO的概率女性43%、男性46%。
- 相比MHNO,MHO的亚临床CVD OR为1.28(95%CI 0.85-1.93),冠状动脉钙化OR为1.92(95%CI 1.38-2.68)。
- 随访期间231例发生糖尿病,784例高血压,423例CKD,639例CVD,1296例死亡。
- 相比MHNO,MHO的糖尿病HR为4.69(95%CI 2.21-9.96),高血压HR为2.21(95%CI 1.66-2.94)。
- 相比MUO,MHO的糖尿病HR为0.21(95%CI 0.12-0.39),CVD HR为0.64(95%CI 0.43-0.95),CKD HR为0.44(95%CI 0.27-0.73)。
临床怎么用
- 临床应动态评估肥胖患者的代谢状态,MHO并非良性状态,需监测代谢异常和临床疾病发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The natural histories of obesity subphenotypes are incompletely delineated. OBJECTIVES: To investigate dynamic changes in obesity subphenotypes and associations with outcomes. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: Framingham Offspring Cohort participants (n = 4291) who attended the examination cycles 2 (1979 to 1983) to 7 (1998 to 2001), which included 26,508 participant observations. Obesity subphenotypes [metabolically healthy nonobese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy nonobese (MUNO), and metabolically unhealthy obese (MUO)] were ascertained based on metabolic health (<2 Adult Treatment Panel III criteria). The outcomes were subclinical cardiovascular disease (CVD), incident diseases [diabetes, hypertension, chronic kidney disease (CKD), CVD], and all-cause mortality. RESULTS: At baseline, 4% and 31% of participants exhibited the MHO and MUNO subphenotypes, respectively. Four-year probability of MHO participants becoming MUO was 43% in women and 46% in men. Compared with MHNO, MHO participants had 1.28-fold (95% CI, 0.85 to 1.93) and 1.92-fold (95% CI, 1.38 to 2.68) higher odds of subclinical CVD and coronary artery calcification, respectively; corresponding values for MUNO were 1.95 (1.54 to 2.47) and 1.92 (1.38 to 2.68). During follow-up (median of 14 years), 231 participants developed diabetes, 784 hypertension, 423 CKD, 639 CVD, and 1296 died. Compared with MHNO, MHO conferred higher risks of diabetes [hazard ratio (HR), 4.69; 95% CI, 2.21 to 9.96] and hypertension (HR, 2.21; 95% CI, 1.66 to 2.94). Compared with MUO, MHO conferred lower risks of diabetes (0.21; 0.12 to 0.39), CVD (0.64; 0.43 to 0.95), and CKD (0.44; 0.27 to 0.73), but similar hypertension, cardiovascular mortality, and overall mortality risks. CONCLUSION: Over time, most MHO participants developed metabolic abnormalities and clinical disease. The MHO subphenotype is a harbinger of future risk.
引用
- Echouffo-Tcheugui JB, Short MI, Xanthakis V, et al. Natural History of Obesity Subphenotypes: Dynamic Changes Over Two Decades and Prognosis in the Framingham Heart Study. J Clin Endocrinol Metab. 2019. PMID: 30339231. doi:10.1210/jc.2018-01321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。